Quantcast

Latest H5N1 clinical trials Stories

e550fce5866b3a14f33c94b35eaad614
2011-01-05 09:36:17

Two doses of the varicella, or chickenpox, vaccine provide excellent protection in children against this highly contagious and, in some cases, severe disease. To be published in the February 1 issue of The Journal of Infectious Diseases, the findings support the two-dose vaccine regimen recommended in the United States since 2006. The Centers for Disease Control and Prevention (CDC) began recommending a single dose of varicella vaccine in children aged 1 to 13 years old in 1995. Although the...

2010-12-28 07:35:00

BEIJING, Dec. 28, 2010 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). According to the approval document, Sinovac is required to conduct each phase of the human clinical trials in accordance with SFDA...

2010-12-22 07:55:00

QUEBEC CITY, QC, Dec. 22 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the last dose of vaccine has been administered completing the first part of the Company's Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine").  The Company expects to present interim Phase II...

2010-12-07 14:24:30

NIH scientists consider prospects for a universal influenza vaccine WHAT: The costly, time-consuming process of making, distributing and administering millions of seasonal flu vaccines would become obsolete if researchers could design a vaccine that confers decades-long protection from any flu virus strain. Making such a universal influenza vaccine is feasible but licensing it may require innovation on several fronts, including finding new ways to evaluate the efficacy of vaccine candidates...

fe9dff98e451ba286dd7a495937cd063
2010-12-07 07:53:07

Only the fragile chicken egg stands between Americans and a flu pandemic that would claim tens of thousands more lives than are usually lost to the flu each year. Vaccine production hinges on the availability of hundreds of millions of eggs "“ and even with the vaccine, flu still claims somewhere around 36,000 lives in the United States during a typical year. Now scientists have taken an important step toward ending the dominance of the oval. In a paper published in the Dec. 6 issue of...

2010-11-29 08:00:00

SWIFTWATER, Pennsylvania, November 29, 2010 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a...

2010-11-11 03:52:00

ITTIGEN and BERN, Switzerland, November 11, 2010 /PRNewswire/ -- Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide. Vaccination of the first study group has been completed and demonstrated that PEV7 is safe and well-tolerated in all subjects and...

2010-11-04 01:00:00

LYON, France, November 4, 2010 /PRNewswire-FirstCall/ -- - First Phase 3 Study Underway in Australia Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate(1,2), entered its first phase 3 clinical study in Australia. This study is part of a global phase 3...

2010-11-02 06:00:00

PRINCETON, N.J., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, reported today that it has completed enrollment of its Phase 1B clinical trial of RiVax(TM), a ricin subunit vaccine, in healthy volunteers. Preliminary results indicate that RiVax(TM) appears safe at all doses tested in volunteers. This trial is designed to assess the duration of immune responses using an adjuvant formulation...

2010-11-01 06:00:00

QUEBEC CITY , Nov. 1 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment of volunteers is now underway. The Phase II randomized, placebo controlled clinical...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related